|Articles|August 10, 2009
OmniComm Systems To Provide eClinical Solutions for two Phase I HIV Studies
Advertisement
OmniComm Systems (Ft. Lauderdale, FL) announced that it has been selected by an unnamed biopharmaceutical company to provide eClinical solutions for two of its Phase I HIV studies involving over 100 patients. Both HIV studies are expected to run for seven months. The company has already used OmniComm Systems in different therapeutic areas.
OmniComm recently announced acquisitions of EDC assets of ERT and Logos Technologies.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement